RET and non-small cell lung carcinoma: The treatment of RET‐rearranged NSCLC has been evolved from chemotherapy‐based combination therapy to multi‐kinase inhibitor (MKI) to selective RET‐tyrosine kinase inhibitors (RET‐TKI) in the past decades.